J. Brandon Birath, PhD. Director of Psychology Training, Olive View-UCLA Medical Center, Los Angeles, CA.
Victoria Hendrick, MD. Chief, Inpatient Psychiatry, Olive View-UCLA Medical Center, Los Angeles, CA; Editor-in-Chief, The Carlat Hospital Psychiatry Report.
Dr. Birath and Dr. Hendrick have no financial relationships with companies related to this material.
David Mintz, MD.
Fellow, American Academy of Psychoanalysis and Dynamic Psychiatry. Staff psychiatrist, Austen Riggs Center, Stockbridge, MA.
Dr. Mintz has no financial relationships with companies related to this material.
Awais Aftab, MD. Psychiatrist in Cleveland, Ohio, and Clinical Assistant Professor of Psychiatry at Case Western Reserve University. He writes an online newsletter, Psychiatry at the Margins. Twitter: @awaisaftab
Dr. Aftab has no financial relationships with companies related to this material.
Allen Frances, MD. Chair of the DSM-IV Task Force; Professor and Chairman Emeritus of the Duke University Department of Psychiatry; founding editor of the Journal of Personality Disorders and the Journal of Psychiatric Practice; and co-host of the podcast Talking Therapy.
Dr. Frances has no financial relationships with companies related to this material.
Bryan K. Tolliver, MD, PhD
Associate professor, Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina. Charleston, SC.
Dr. Tolliver has no financial relationships with companies related to this material.
“When tailoring medication choice, a careful history can guide you. If I’m treating a patient who drinks excessively at night to sleep or who struggles with insomnia when they try to stop drinking, I’ll start with a sedating antidepressant like mirtazapine. That’s not an evidence-based decision, it’s a clinical decision that I think can be helpful.”
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
